The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Blood

Volumn 116, Issue 22, 2010, Pages 4532-4541

  Hudecek, Michael ^a,b   Schmitt, Thomas M ^a   Baskar, Sivasubramanian ^c   Lupo Stanghellini, Maria Teresa ^a,d   Nishida, Tetsuya ^a   Yamamoto, Tori N ^a   Bleakley, Marie ^a,e   Turtle, Cameron J ^a,e   Chang, Wen Chung ^f   Greisman, Harvey A ^e   Wood, Brent ^e   Maloney, David G ^a,e   Jensen, Michael C ^a,g   Rader, Christoph ^c   Riddell, Stanley R ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOFETAL ANTIGEN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; EMBRYONIC STEM CELL; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MANTLE CELL LYMPHOMA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 78649461928     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-283309     Document Type: Article

References (36)

1. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. J Clin Oncol. 2008; 26(30):4912-4920.
2. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104(12):3535-3542.
3. Nishida T, Hudecek M, Kostic A, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res. 2009;15(14):4759-4768.
4. Hudecek M, Anderson LJ, Nishida T, Riddell S. Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol. 2009;2(5):517-532.
5. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002; 20(1):70-75. (Pubitemid 34044918)
6. Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18(8):712-725.
7. Jensen MC, Popplewell L, Cooper LJ, et al. Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245-1256.
8. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271.
9. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187-198.
10. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605-611.
11. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625-1638.
12. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194(11):1639-1647.
13. Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396-404.
14. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008;123(5): 1190-1195.
15. Forrester WC. The Ror receptor tyrosine kinase family. Cell Mol Life Sci. 2002;59(1):83-96. (Pubitemid 34117358)
16. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008;105(8):3047-3052. (Pubitemid 351723665)
17. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol. 2005;7(6): 591-600. (Pubitemid 40796982)
18. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128(2):189-201.
19. Ware CB, Nelson AM, Blau CA. A comparison of NIH-approved human ESC lines. Stem Cells. 2006;24(12):2677-2684.
20. Draper JS, Pigott C, Thomson JA, Andrews PW. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat. 2002;200(Pt 3):249-258. (Pubitemid 34467317)
21. Schmitt TM, Ciofani M, Petrie HT, Zuniga-Pflucker JC. Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions. J Exp Med. 2004; 200(4):469-479.
22. Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9(4): 577-586.
23. Foster AE, Okur FV, Biagi E, et al. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010;24(3):563-572.
24. Shabani M, Asgarian-Omran H, Vossough P, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2008; 49(7):1360-1367.
25. Green H, Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell. 1974;3(2):127-133.
26. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985;100(3):965-973.
27. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267(36):26181-26190.
28. Wood B. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol. 2004;75:559-576.
29. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7): 1797-1805.
30. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
31. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294-305.
32. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464): 645-648.
33. Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98(4): 1166-1173.
34. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010; 115(13):2619-2629.
35. Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol. 2007;20(3): 385-397.
36. Fulcher DA, Basten A. B cell life span: a review. Immunol Cell Biol. 1997;75(5):446-455.